Patents by Inventor Man-Un Ung

Man-Un Ung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lactams as CBL-B inhibitors selective over C-CBL
    Patent number: 12187709
    Abstract: A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: January 7, 2025
    Assignee: Genentech, Inc.
    Inventors: Malcolm Huestis, Michael John Lambrecht, Jun Liang, Man Un Ung, Xiaojing Wang, Jason Robert Zbieg, Bing-Yan Zhu, Lisa Marie Barton, Fabio Broccatelli, Georgette Marie Castanedo, Araz Jakalian, Robin Larouche-Gauthier, Arun Yadav
  • AMIDES AS CBL-B INHIBITORS
    Publication number: 20240300927
    Abstract: Various amide compounds that bind Cbl-B, including those that are selective for C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Araz Jakalian, Michael John Lambrecht, Robin Larouche-Gauthier, Malcolm Huestis, Man Un Ung, Xiaojing Wang, Arun Yadav, Jason Robert Zbieg, Fabio Broccatelli
  • LACTAMS AS CBL-B INHIBITORS SELECTIVE OVER C-CBL
    Publication number: 20230212153
    Abstract: A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.
    Type: Application
    Filed: November 4, 2022
    Publication date: July 6, 2023
    Applicant: Genentech, Inc.
    Inventors: Malcolm HUESTIS, Michael John LAMBRECHT, Jun LIANG, Man Un UNG, Xiaojing WANG, Jason Robert ZBIEG, Bing-Yan Zhu, Lisa Marie BARTON, Fabio BROCCATELLI, Georgette Marie CASTANEDO, Araz JAKALIAN, Robin LAROUCHE-GAUTHIER, Arun YADAV
  • LACTAMS AS CBL-B INHIBITORS
    Publication number: 20230079990
    Abstract: Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: March 16, 2023
    Applicant: Genentech, Inc.
    Inventors: Jun LIANG, Araz JAKALIAN, Michael John LAMBRECHT, Robin LAROUCHE-GAUTHIER, Malcolm HUESTIS, Man Un UNG, Xiaojing WANG, Arun YADAV, Jason Robert ZBIEG, Fabio BROCCATELLI
  • Kinase inhibitor compounds and compositions and methods of use
    Patent number: 11547712
    Abstract: The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R5, R6, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: January 10, 2023
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Robert Devita, Andrew Stewart, Avner Schlessinger, Kunal Kumar, Peter Man-Un Ung, Hui Wang, Hailing Li
  • Compositions and Methods for Treating or Preventing Endocrine FGF23-Linked Diseases
    Publication number: 20200331978
    Abstract: The present invention provides compositions and methods that are useful in treating or preventing endocrine FGF-related diseases or disorders, such as but not limited to dysfunctional phosphate homeostasis and chronic kidney disease (CKD).
    Type: Application
    Filed: December 12, 2018
    Publication date: October 22, 2020
    Inventors: Joseph Schlessinger, Sangwon Lee, Avner Schlessinger, Man-Un Ung
  • KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20200306257
    Abstract: The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R5, R6, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
    Type: Application
    Filed: November 20, 2018
    Publication date: October 1, 2020
    Inventors: Robert DEVITA, Andrew STEWART, Avner SCHLESSINGER, Kunal KUMAR, Peter MAN-UN UNG, Hui WANG, Hailing LI